ISO-66, a novel inhibitor of macrophage migration inhibitory factor, shows efficacy in melanoma and colon cancer models

International Journal of Oncology

Volumn 45, Issue 4, 2014, Pages 1457-1468

  Ioanou, Kyriaki ^a   Cheng, Kai Fan ^b   Crichlow, Gregg V ^c   Birmpilis, Anastasios I ^a   Lolis, Elias J ^c   Tsitsilonis, Ourania E ^a   Al Abed, Yousef ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Colon; ISO 66; Melanoma; MIF; Mif inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; ISO 66; UNCLASSIFIED DRUG; 3-(4-HYDROXYPHENYL)-4,5-DIHYDRO-5-ISOXAZOLEACETIC ACID METHYL ESTER; ISO-66; ISOXAZOLE DERIVATIVE; MACROPHAGE MIGRATION INHIBITION FACTOR; MOLECULAR LIBRARY; PHENOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; DRUG SYNTHESIS; EFFECTOR CELL; EX VIVO STUDY; GROWTH RATE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE MIGRATION INHIBITION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; ENZYME ACTIVE SITE; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; MOLECULAR LIBRARY; NUDE MOUSE; PATHOLOGY; SPLEEN; SYNTHESIS; THERAPEUTIC USE;

ANIMALS; ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; ISOXAZOLES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MELANOMA; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PHENOLS; SMALL MOLECULE LIBRARIES; SPLEEN;

EID: 84907471315     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2551     Document Type: Article

References (44)

1. Al-Abed Y and VanPatten S: MIF as a disease target: ISO-1 as a proof-of-concept therapeutic. Future Med Chem 3: 45-63, 2011.
2. Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R and Bacher M: The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 115: 2031-2040, 2009.
3. Girard E, Strathdee C, Trueblood E and Queva C: Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16 F10 melanoma model. Br J Cancer 107: 1498-1505, 2012.
4. Choi S, Kim HR, Leng L, Kang I, Jorgensen WL, Cho CS, Bucala R and Kim WU: Role of macrophage migration inhibitory factor in the regulatory T cell response of tumor-bearing mice. J Immunol 189: 3905-3913, 2012.
5. Yaddanapudi K, Putty K, Rendon BE, Lamont GJ, Faughn JD, Satoskar A, Lasnik A, Eaton JW and Mitchell RA: Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. J Immunol 190: 2984-2993, 2013.
6. Krockenberger M, Kranke P, Hausler S, Engel JB, Horn E, Nurnberger K, Wischhusen J, Dietl J and Honig A: Macrophage migration-inhibitory factor levels in serum of patients with ovarian cancer correlates with poor prognosis. Anticancer Res 32: 5233-5238, 2012.
7. Kindt N, Lechien J, Decaestecker C, Rodriguez A, Chantrain G, Remmelink M, Laurent G, Gabius HJ and Saussez S: Expression of macrophage migration-inhibitory factor is correlated with progression in oral cavity carcinomas. Anticancer Res 32: 4499-4505, 2012.
8. Wang XB, Tian XY, Li Y, Li B and Li Z: Elevated expression of macrophage migration inhibitory factor correlates with tumor recurrence and poor prognosis of patients with gliomas. J N eurooncol 106: 43-51, 2012.
9. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R and Vera PL: Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU 145 prostate cancer cells. J Immunol 177: 8730-8739, 2006. (Pubitemid 44893839)
10. Rendon BE, Roger T, Teneng I, Zhao M, Al-Abed Y, Calandra T and Mitchell RA: Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem 282: 29910-29918, 2007. (Pubitemid 350035289)
11. Lubetsky JB, Dios A, Han J, Aljabari B, Ruzsicska B, Mitchell R, Lolis E and Al-Abed Y: The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem 277: 24976-24982, 2002. (Pubitemid 34951799)
12. Al-Abed Y, Dabideen D, Aljabari B, Valster A, Messmer D, Ochani M, Tanovic M, Ochani K, Bacher M, Nicoletti F, Metz C, Pavlov VA, Miller EJ and Tracey KJ: ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 280: 36541-36544, 2005. (Pubitemid 41587728)
13. Winner M, Meier J, Zierow S, Rendon BE, Crichlow GV, Riggs R, Bucala R, Leng L, Smith N, Lolis E, Trent JO and Mitchell RA: A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res 68: 7253-7257, 2008.
14. Schrader J, Deuster O, Rinn B, Schulz M, Kautz A, Dodel R, Meyer B, Al-Abed Y, Balakrishnan K, Reese JP and Bacher M: Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdown. BMC Cancer 9: 464, 2009.
15. Piette C, Deprez M, Roger T, Noel A, Foidart JM and Munaut C: The dexamethasone-induced inhibition of proliferation, migration, and invasion in glioma cell lines is antagonized by macrophage migration inhibitory factor (MIF) and can be enhanced by specific MIF inhibitors. J Biol Chem 284: 32483-32492, 2009.
16. He XX, Chen K, Yang J, Li XY, Gan HY, Liu CY, Coleman TR and Al-Abed Y: Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med 15: 1-10, 2009.
17. Barnick JWFK, Van Der Baan JL and Bickelhaupt F: Convenient direct method for the preparation of keto-acids. Synthesis 79: 787-788, 1979.
18. Rathkea MW and Nowaka MA: Synthesis of beta-keto acids and methyl ketones using bis(trimethylsilyl) malonate and triethylamine in the presence of lithium or magnesium Halides. Synthesis Communications 15: 1039-1049, 1985.
19. Sun HW, Swope M, Cinquina C, Bedarkar S, Bernhagen J, Bucala R and Lolis E: The subunit structure of human macrophage migration inhibitory factor: evidence for a trimer. Protein Eng 9: 631-635, 1996. (Pubitemid 26275709)
20. Crichlow GV, Cheng KF, Dabideen D, Ochani M, Aljabari B, Pavlov VA, Miller EJ, Lolis E and Al-Abed Y: Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor. J Biol Chem 282: 23089-23095, 2007. (Pubitemid 47311928)
21. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read R J, Rice LM, Simonson T and Warren GL: Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54: 905-921, 1998.
22. Argyropoulou A, Samara P, Tsitsilonis O and Skaltsa H: Polar constituents of Marrubium thessalum Boiss. & Heldr. (Lamiaceae) and their cytotoxic/cytostatic activity. Phytother Res 26: 1800-1806, 2012.
23. + T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 164: 3902-3912, 2000.
24. Skopeliti M, Voutsas IF, Klimentzou P, Tsiatas ML, Beck A, Bamias A, Moraki M, Livaniou E, Neagu M, Voelter W and Tsitsilonis OE: The immunologically active site of prothymosin alpha is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients. Cancer Immunol Immunother 55: 1247-1257, 2006. (Pubitemid 43992051)
25. Nair SK, Boczkowski D, Snyder D and Gilboa E: Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 27: 589-597, 1997. (Pubitemid 27110569)
26. Ioannou K, Kavrochorianou N, Bega C, Thyphronitis G, Haralambous S and Tsitsilonis O: The C-Terminal decapeptide of prothymosin α induces a TH1-Type immune response in vitro and retards tumor growth in vivo. 8th Joint Conference of the International Cytokine Society and the International Society for Interferon and Cytokine Research Elsevier, Chicago, IL, pp17-20, 2010.
27. Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M and Nishihira J: High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 264: 751-758, 1999.
28. Dessein AF, Stechly L, Jonckheere N, Dumont P, Monte D, Leteurtre E, Truant S, Pruvot FR, Figeac M, Hebbar M, Lecellier CH, Lesuffleur T, Dessein R, Grard G, Dejonghe MJ, de Launoit Y, Furuichi Y, Prevost G, Porchet N, Gespach C and Huet G: Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells. Cancer Res 70: 4644-4654, 2010.
29. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ and Beach DH: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190: 1375-1382, 1999.
30. Sun B, Nishihira J, Suzuki M, Fukushima N, Ishibashi T, Kondo M, Sato Y and Todo S: Induction of macrophage migration inhibitory factor by lysophosphatidic acid: relevance to tumor growth and angiogenesis. Int J Mol Med 12: 633-641, 2003.
31. Sun B, Nishihira J. Yoshiki T, Kondo M, Sato Y, Sasaki F and Todo S: Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res 11: 1050-1058, 2005. (Pubitemid 40175753)
32. Apte RS, Sinha D, Mayhew E, Wistow GJ and Niederkorn JY: Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol 160: 5693-5696, 1998. (Pubitemid 28298023)
33. Yan X, Orentas RJ and Johnson BD: Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. Cytokine 33: 188-198, 2006.
34. Krockenberger M, Dombrowski Y., Weidler C, Ossadnik M, Honig A, Hausler S, Voigt H, Becker JC, Leng L, Steinle A, Weller M, Bucala R, Dietl J and Wischhusen J: Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol 180: 7338-7348, 2008.
35. Xu L, Li Y, Sun H, Zhen X, Qiao C, Tian S and Hou T: Current developments of macrophage migration inhibitory factor (MIF) inhibitors. Drug Discov Today 18: 592-600, 2013.
36. Binsky I, Lantner F, Grabovsky V, Harpaz N, Shvidel L, Berrebi A, Goldenberg DM, Leng L, Bucala R, Alon R, Haran M and Shachar I: TAp63 regulates VLA-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner. J Immunol 184: 4761-4769, 2010.
37. Ioannou K, Samara P, Livaniou E, Derhovanessian E and Tsitsilonis OE: Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy. Cancer Immunol Immunother 61: 599-614, 2012.
38. West PW, Parker LC, Ward JR and Sabroe I: Differential and cell-type specific regulation of responses to Toll-like receptor agonists by ISO-1. Immunology 125: 101-110, 2008.
39. Chuang CC, Chuang YC, Chang WT, Chen CC, Hor LI, Huang AM, Choi PC, Wang CY, Tseng PC and Lin CF: Macrophage migration inhibitory factor regulates interleukin-6 production by facilitating nuclear factor-kappa B activation during Vibrio vulnificus infection. BMC Immunol 11: 50, 2010.
40. Ogawa H, Nishihira J, Sato Y, Kondo M, Takahashi N, Oshima T and Todo S: An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. Cytokine 12: 309-314, 2000. (Pubitemid 30449820)
41. Takahashi K, Koga K, Linge HM, Zhang Y, Lin X, Metz CN, Al-Abed Y, Ojamaa K and Miller EJ: Macrophage CD74 contributes to MIF-induced pulmonary inflammation. Respir Res 10: 33, 2009.
42. Imai K and Takaoka A: Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6: 714-727, 2006. (Pubitemid 44286003)
43. Engh RA and Huber R: Accurate bond and angle parameters for X-ray protein structure refinement. Acta Cryst 47: 392-400, 1991.
44. Cho Y, Crichlow GV, Vermeire JJ, Leng L, Du X, Hodsdon ME, Bucala R, Cappello M, Gross M, Gaeta F, Johnson K and Lolis EJ: Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci USA 107: 11313-11318, 2010.